<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>18 Soft tissue sarcomas</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part23.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part25.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark24" class="s95" name="bookmark67">Chapter 18</a><a name="bookmark68">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 49pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_268.png"/></span></p><p style="padding-top: 4pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark24">Soft tissue sarcomas</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 48pt;text-indent: 0pt;line-height: 109%;text-align: left;">Morag Brothwell, sarah prewett, Gail horan, and emma-louise Gerety</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 12pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Soft (connective) tissue sarcomas are a rare, heterogeneous group of malignancies constituting less than 1% of all adult cancers. There are over 50 different histo- logical subtypes according to the 2013 World Health Organization classification, with pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumours accounting for over 75% cases.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">They can arise almost anywhere in the body, but approximately 75% affect the extremities (legs &gt; arms), with other common sites being the trunk wall, retroperitoneum, and head and neck. The dominant pattern of metastatic spread is haematogenous to the lungs, and less commonly bone and liver. Lymphatic spread is rare, but may be more common in certain subtypes such as epithelioid and syn- ovial sarcomas.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The mainstay of radical treatment includes radiotherapy and surgery, the order depending on factors such as the site and histology of the primary. Biopsy of suspected soft tissue sarcoma should be planned and performed at a specialist sarcoma centre, so that the biopsy site can be marked and the tract then incorporated into the surgery and/or radiotherapy field, minimizing the risk of seeding. This chapter will discuss the different imaging modalities involved in the diagnosis, staging, response to treatment, and follow-up for soft tissue sarcomas, with an emphasis on those arising in the ex- tremities or superficial tissues.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">18.2 <span class="h4">Diagnosis and staging</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Ultrasound (US) and magnetic resonance imaging (MRI) are the most important imaging modalities for characterizing soft tissue lesions. However, radiographs, com- puted tomography (CT) and positron emission tomography (PET)/CT using 18- fluoride labelled fluorodeoxyglucose (FDG) can all play a role in diagnosis and staging (Table 18.1). Superficial sarcomas such as angiosarcomas may have significant skin in- volvement, often best appreciated clinically, and in these cases photography and clin- ical assessment are also crucial.</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Table 18.1 <span class="s52">the use of different imaging modalities in the diagnosis, staging, and follow- up of patients with soft tissue sarcomas</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:14pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" rowspan="2"><p class="s26" style="padding-top: 1pt;padding-right: 21pt;text-indent: 0pt;line-height: 112%;text-align: left;">Imaging modality</p></td><td style="width:253pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Location of soft tissue lesion</p></td></tr><tr style="height:24pt"><td style="width:111pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;line-height: 112%;text-align: left;">Extremity/superficial layers of the trunk/head and neck</p></td><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Deep thorax/abdomen/pelvis</p></td></tr><tr style="height:26pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-right: 21pt;text-indent: 0pt;line-height: 111%;text-align: left;">ultrasound (with Doppler)</p></td><td style="width:111pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">First-line imaging</p></td><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">May be first-line imaging (pelvis)</p></td></tr><tr style="height:15pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">MRi</p></td><td style="width:111pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Definitive imaging/follow-up</p></td><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">First-line/definitive imaging/follow-up</p></td></tr><tr style="height:26pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Ct</p></td><td style="width:111pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">staging/follow-up</p></td><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;padding-right: 23pt;text-indent: 0pt;line-height: 111%;text-align: left;">May be first-line imaging/staging/ follow-up</p></td></tr><tr style="height:15pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">[18F]-FDG-pet</p></td><td style="width:111pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">staging/follow-up</p></td><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">staging/follow-up</p></td></tr><tr style="height:26pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Radiograph</p></td><td style="width:111pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-right: 21pt;text-indent: 0pt;line-height: 111%;text-align: left;">staging (lung metastases), follow-up</p></td><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">staging (lung metastases), follow-up</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 109%;text-align: left;">imaging is important for determining the size of the primary and categorizing it as superficial or deep, detection of lymph node involvement and distant metastases. the stage grouping (i–iV) then incorporates tnM staging and histological grade.</p><p class="s14" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 107%;text-align: left;">source: data from sobin lh, Gospodarowicz MK, Wittekind Ch (2017). <span class="s83">UICC TNM Classification of Malignant Tumours </span>(eighth edn). oxford: Wiley Blackwell.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">18.2.1 <span class="s29">Ultrasound</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">US utilizes subtle differences in acoustic impedance of different soft tissues to ultra-high frequency sounds waves. US is recommended for first-line evaluation of soft tissue masses in the trunk wall and extremities and also for investigation of female pelvic masses.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Tumours are measured in three planes to assess their size and precise location, in addition to their internal sonographic characteristics. Additional use of Doppler US allows evaluation of the vascularity of the tumour and involvement of adjacent vessels (Figure 18.1). There is some evidence that contrast-enhanced Doppler ultrasound may be more sensitive than Doppler ultrasound alone in determining hypervascularity and the likelihood of malignancy.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Dynamic US (scanning whilst the patient moves) can help assess tumours of the distal extremities and their relationship with tendons and small muscles of the hand.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="405" height="115" alt="image" src="Image_269.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 18.1 <span class="s52">us imaging in a 19-year-old male with an alveolar soft part tumour in the popliteal fossa. B-mode grey-scale us image (a) of the popliteal fossa mass and corresponding Doppler us (b) demonstrates hypervascularity within the mass. us-guided core biopsy of the mass</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">(c) shows the hyper-echoic, linear biopsy needle (arrows) within the mass.</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The initial US may rule out the need for further investigation if the findings strongly support a benign process such as a lipoma or a simple cyst. Caution and close follow- up may be needed with the interpretation of trauma-related haematoma to ensure that it is not due to haemorrhagic sarcoma.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Lipomatous lesions appear hyperechoic (brighter) on US, whereas fluid and fresh blood appear anechoic (dark), with posterior acoustic enhancement (a brighter shadow deep to the lesion). Sonographic features of concern for malignancy include a maximum diameter &gt;7 cm (for lipomatous lesions), hypervascularity, heterogeneity, and involvement of the deep tissues. Clinical features are also important, such as pain or rapid growth. In these situations, further characterization with MRI is required.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Biopsies are usually US-guided for superficial masses and CT-guided for deep, intra- abdominal masses. Endoscopic US may be used to biopsy lesions close to the bronchi, oesophagus, or distal bowel. Uterine masses are usually biopsied via hysteroscopy under direct visualization. Although rarely required, echocardiograms can be used to characterize soft tissue sarcomas arising from the myocardium or pericardium and assess their effect on cardiac function.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Although very useful as an initial and rapid investigation, there are limitations of US as a modality. These include reduced resolution with increased lesion depth and significant inter-operator variability. Therefore, if US is concerning for malignancy, or the deep extent of the lesion cannot be completely determined, MRI is performed.</p><p class="s97" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18.2.2 <span class="s29">Magnetic resonance imaging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">MRI provides definitive imaging for both superficial and deep soft tissue tumours which have been demonstrated by US or CT. Table 18.2 shows the different MRI sequences commonly used for imaging of soft tissue sarcomas.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI is performed in at least two planes, according the location and shape of the mass (Figure 18.2). T1-weighted images and fat suppressed T2-weighted images are acquired first. The T1-weighted image is used for the assessment of fat content; fat is high signal (bright) and water is low signal (dark). Non-lipomatous tumour and muscle typically have a similar intermediate T1-weighted signal and are difficult to differentiate.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">On T2-weighted images, fat, water, and cellular material all have high signal. Fat suppression can be applied, using techniques such as spectral fat saturation or short T1 inversion recovery (STIR). On fat saturated T2-weighted sequences, water is of high</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table 18.2 <span class="s52">MRi sequences for characterization of soft tissue sarcomas</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:14pt"><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Sequence</p></td><td style="width:233pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">Demonstrates</p></td></tr><tr style="height:15pt"><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1-weighted</p></td><td style="width:233pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">Fat (also blood products, melanin, high protein content fluid)</p></td></tr><tr style="height:26pt"><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 111%;text-align: left;">t2-weighted with fat saturation (fs)</p></td><td style="width:233pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">Fluid (fat signal suppressed)</p></td></tr><tr style="height:26pt"><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 111%;text-align: left;">t1-weighted fs post iV gadolinium</p></td><td style="width:233pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 12pt;text-indent: 0pt;line-height: 111%;text-align: left;">enhancement of vascular/solid masses; non-enhancement of fluid—differentiation of cystic areas</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="404" height="344" alt="image" src="Image_270.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 18.2 <span class="s52">MRi in a 63-year-old female with an undifferentiated spindle cell/ pleiomorphic sarcoma (arrow) in the vastus lateralis muscle. Coronal t1-weighted image</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">(a) demonstrates the mass as isointense to muscle with no internal fat signal. Coronal t2-weighted fat saturated image (b) demonstrates the lesion is of heterogeneous, high fluid-sensitive signal. Corresponding axial t1-weighted (c), axial t2 fat saturated (d) and axial t1 fat saturated post iV gadolinium (e) images.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">signal (bright). It may not be possible to determine whether the high signal is due to high intra-cellular water content in a solid lesion or cyst.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Intravenous para-magnetic contrast agents containing gadolinium can be admin- istered which will be preferentially distributed to vascular structures, such as solid sarcomas, inflammatory lesions, and normal structures such as synovium. If the initial MRI shows that the lesion is of high T1-weighted signal, the lesion contains fat and gadolinium is not required.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">If the lesion is of high T2-weighted signal, it may not be clear whether this rep- resents water or high water-containing cellular material. Therefore, fat suppressed T1-weighted pre- and post-intravenous gadolinium images may be acquired. Of note there is growing concern that the gadolinium used in MRI leads to long-term gado- linium deposition in the brain, liver, and skin, the consequences of which are un- known. Long-term data is needed, but the potential risks of intravenous gadolinium are currently outweighed by the benefit of accurate diagnosis and follow-up.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI allows determination of the size, character, location, and involvement of sur- rounding structures and fascial planes. MRI characteristics are similar for many</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: right;">histological subtypes of soft tissue sarcoma. They are typically heterogeneous masses composed of cellular, myxoid, necrotic, and/or haemorrhagic components. Contrast en- hancement is often more pronounced in the cellular tumour periphery. They may be lobulated and have septations and they can exert pressure on surrounding structures. They also have a tendency to grow along fascial planes on a path of least resistance. Biopsy and clinical correlation are always needed for a definitive diagnosis, which allows determination of the sarcoma subtype and grade; both important prognostic indicators. Despite the similar MRI-characteristics seen across many histological subtypes of sarcoma, there are some specific imaging features which are associated with particular sarcoma subtypes, such as fat content, cerebral metastases, lymph node metastases, and anatomical location. These are considered separately below. Calcification and</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">bone involvement are best appreciated on CT and are covered later in the chapter.</p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18.2.2.1 <span class="s98">Fat content</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Fat shows a high signal intensity on T1- and T2-weighted MRI but loss of signal on fat-suppressed images (Figure 18.3). Soft tissue sarcomas that typically contain fat in- clude the adipocytic subtypes: well-differentiated, dedifferentiated, pleomorphic, and myxoid liposarcomas. The differential for a fat-containing lesion also includes benign lesions such as lipoma, haemangioma, or teratoma. Well-differentiated liposarcomas are often oval, round, or lobulated. At MRI, the amount of fat generally corresponds to the degree of differentiation, with dedifferentiated liposarcomas containing less, or sometimes no discernible fat on MRI. The presence of septations or solid enhancing elements may suggest dedifferentiation.</p><p class="s97" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18.2.2.2 <span class="s98">Anatomical location</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Anatomical location may provide clues as to the sarcoma subtype. Sarcomas which tend to be superficially located include myxofibrosarcoma, angiosarcoma, epithelioid sarcoma, leiomyosarcoma, and epithelioid haemangioendothelioma. Subtypes as- sociated with tendons include synovial sarcoma, clear cell sarcoma, and epithelioid sarcoma. Synovial sarcomas are typically multilobulated, septated masses of the ex- tremities, often found in the deep soft tissues around the knee and adjacent to joints and tendon sheaths. Peripheral nerve sheath tumours (PNSTs) tend to be fusiform masses with tapered ends, continuous with a nerve and possibly associated with mus- cular atrophy. In contrast to benign PNSTs, malignant lesions tend to be larger, with more ill-defined margins and surrounding oedema.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Retroperitoneal sarcomas are most commonly found to be liposarcomas or leiomyosarcomas. Retroperitoneal leiomyosarcomas may appear on imaging as a large, heterogeneous, necrotic mass contiguous with a vessel (usually the inferior vena cava below the level of the hepatic veins). Uterine leiomyosarcomas are commonly large infiltrating myometrial masses with low-intermediate signal intensity on T1-weighted images and high signal on T2-weighted images. Although a detailed consideration of retroperitoneal and uterine sarcomas is outside the scope of this chapter, diffusion weighted imaging in MRI may be useful in differentiating uterine leiomyomas from leiomyosarcomas.</p><p class="s97" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18.2.2.3 <span class="s98">Lymph node metastasis</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Lymph node metastasis is rare but can occur in epithelioid sarcoma, synovial sarcoma, rhabdomyosarcoma, clear cell sarcoma, and angiosarcoma. This may be evaluated on</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="405" height="269" alt="image" src="Image_271.png"/></span></p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 18.3 <span class="s52">MRi imaging of lipomatous lesions with t1 weighted, fat-sensitive images (a, b, c) and t2-weighted water-sensitive, fat suppressed images (d, e, f). Coronal</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">images (a, d) of a benign, intramuscular lipoma (arrow) in the medial gastrocnemius of a 58-year-old male with complete loss of signal on fat suppressed images. axial images (b, e) of a low grade, well differentiated liposarcoma (arrow) in the posterior thigh of a 50-year-old male with partial fat, partial water-sensitive signal. axial images (c, f) of a myxoid liposarcoma (arrow) in the anterior thigh of a 60-year-old female with minimal fat-sensitive signal and high t2-weighted signal.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">the MRI if local lymph node groups are included in the field of view, but are better as- sessed by a staging CT.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">18.2.2.4 <span class="s98">Central nervous system metastasis</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Clear cell sarcoma, alveolar soft part sarcoma, angiosarcoma, and myxoid liposarcoma are at greatest risk of CNS spread and may warrant MRI of the head as part of staging. T1-weighted images post intravenous gadolinium are acquired as there is little fat in the brain and so enhancement is not obscured by fat signal (Figure 18.4).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">18.2.3 <span class="s29">Computed tomography</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">High resolution, isotropic CT images are acquired which can be reformatted in the coronal and sagittal planes. Lesions in the thorax, abdomen, or pelvis may be dis- covered on CT performed to investigate symptoms when there is no palpable mass (Figure 18.5). Significant findings are usually then evaluated with MRI.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT may be helpful in characterization of primary lesions which are calcified or eroding adjacent bone and also in patients in whom MRI is contraindicated. Calcification often arises in a chronic, benign lesion but can also be seen in soft tissue sarcomas. It is best appreciated on CT or radiograph. It occurs most commonly in liposarcomas, undiffer- entiated pleomorphic sarcomas, and synovial sarcomas. Calcification in a liposarcoma</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="382" height="403" alt="image" src="Image_272.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 18.4 <span class="s52">MRi detection of metastases. axial t1-weighted contrast enhanced images showing (a) brain metastasis (arrow) and (b) dural metastasis (arrow) in a 19-year- old male with alveolar soft part tumour in the popliteal fossa. Coronal t1-weighted</span></p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">(c) and coronal t2-weighted fat saturated (d) image of multiple femoral and pelvic bone metastases (arrows) in a 24-year-old male with synovial sarcoma in the thigh. the</p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">metastases replace the normal fatty marrow and return low t1-weighted signal and high t2-weighted signal compared to normal bone marrow.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">can be large and coarse and may represent dedifferentiation with poor prognosis (Figure 18.5) but can also indicate inflammatory or sclerosing variants of well differen- tiated liposarcomas. Calcification in synovial sarcomas can be fine and stippled.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Bone may be eroded by pressure effect of a high-grade tumour growing in a con- fined space, or by direct invasion (Figure 18.5). This is associated with higher grade sarcomas and is most typically seen in dedifferentiated liposarcoma, undifferentiated pleomorphic rhabdomyosarcomas, and synovial sarcomas.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT is routinely used for staging of soft tissue sarcoma, usually scanning the chest, abdomen, and pelvis (Figure 18.6). Lung is the most common site of metastasis and pulmonary metastases are present in around 10% of patients at presentation. CT thorax without intravenous contrast detects lung metastases which are dense com- pared to the low-density, air-filled normal pulmonary tissues. Liver metastases may</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 45pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="193" height="169" alt="image" src="Image_273.png"/></span></p><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(b)</p><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="142" height="169" alt="image" src="Image_274.png"/></span></p><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(c)</p><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="196" height="168" alt="image" src="Image_275.png"/></span></p><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(a)</p><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s122" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(a)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 18.5 <span class="s52">Ct characterization of primary soft tissue sarcomas. axial Ct post iV contrast medium (a) in the portal venous phase in an 83-year-old female showing a heterogeneous, soft tissue mass in the pelvis (arrow), likely originating from the right</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">ovary, histologically a leiomyosarcoma. axial Ct post iv contrast medium (b) in the portal venous phase in a 53-year-old male showing a large, retroperitoneal, heterogeneous mass with internal calcified septations (arrow), histologically a dedifferentiated liposarcoma. axial Ct post iV contrast medium (c) of a solitary fibrous tumour in an 89-year-old female. there is a large, heterogeneous mass in the right neck (arrow), with destruction of the right posterior arch of the C1 vertebra and extending into the spinal canal.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">not be demonstrated without IV contrast medium, without which they may be of similar density to liver parenchyma. Lung metastases may be nodular, cavitating, or have a ground glass ‘halo’ appearance if there is surrounding haemorrhage, character- istic of lung metastases from epithelioid angiosarcoma (Figure 18.6).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">18.2.4 <span class="s29">Radiographs</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiographs remain important in oncological imaging as they are easily obtained, in- expensive, and quick to acquire. Those sarcomas that become calcified may be first detected by radiograph. Even a non-calcified, large soft tissue mass will be evident on a radiograph although it is usually difficult to precisely localize the mass on the 2D image. For low-grade sarcomas with a low risk of metastasis, a chest radiograph alone may be used to screen for lung metastases (Figure 18.7). Occasionally chest symptoms may the first presentation. Radiographs are also used as a simple screen for bone me- tastases if patients develop significant bone pain.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="396" height="293" alt="image" src="Image_276.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 18.6 <span class="s52">Detection of metastases by Ct. pulmonary nodular metastases (a, arrows; mediastinal windowing) and liver metastases (b, arrowhead; abdominal windowing) and left rib synovial sarcoma recurrence (arrow) in a 24-year-old female. Cavitating lung metastases (c, arrows; lung windowing) with a small pneumothorax (arrowhead) in a 56-year-old female with endometrial stromal sarcoma. solid/ground glass metastases (d, arrows; lung windowing) in a 29-year-old male with an epithelioid angiosarcoma in the deltoid muscle.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18.2.5 <span class="s29">Nuclear imaging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Nuclear imaging uses radionuclides attached to molecules (radiolabelling with tracers) which are injected intravenously prior to imaging. This radioactivity is subsequently detected and then reported as SUV: standard uptake value. There are a variety of dif- ferent radioactive tracers in use but FDG is most often used in soft tissue sarcoma imaging and is taken up by metabolically active tissues.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There is currently no routine role for FDG PET/CT in the diagnosis and staging of soft tissue sarcomas, but it may be useful in certain circumstances. Many soft tissue sarcomas are FDG-avid, but uptake is variable. FDG PET/CT can usually distinguish benign tumours from high-grade soft tissue sarcomas, but cannot reliably distinguish them from low or intermediate grade sarcomas. One notable exception is malignant PNSTs, which show consistently high uptake in contrast to benign PNSTs, with a high sensitivity and specificity for malignant change (Figure 18.8).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 90%;text-align: justify;">Small-scale studies and retrospective analyses of mixed soft tissue sarcoma subtypes suggest that SUV<span class="s36">max </span>may correlate with the probability of recurrence and prognosis and that variation in SUV can provide information about the heterogeneity of the tumour which might be of use at biopsy. With the exception of malignant PNSTs, there is only a small proportion of cases in which FDG PET/CT can add value to the</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">staging and follow-up in patients with soft tissue sarcomas. This is likely because the typical pattern of spread is haematogenous to the lungs and CT chest is currently very</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="303" height="276" alt="image" src="Image_277.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 18.7 <span class="s52">Detection of multiple pulmonary metastases by chest radiograph of a 24-year- old male with synovial sarcoma in the thigh.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="412" height="289" alt="image" src="Image_278.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s123" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s123" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s123" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 18.8 <span class="s52">Mediastinal malignant peripheral nerve sheath tumour (arrow) in a 25-year-old male. axial t1-weighted MRi (a) shows no fat within the lesion. axial t2-weighted fat saturated MRi (b) shows water content of the lesion. Coronal non-contrast Ct (c), FDG pet (d) and fused FDG pet/Ct image (e) shows tumour uptake with background uptake also in the heart (arrowhead).</span></p><p style="padding-top: 4pt;padding-left: 6pt;text-indent: 0pt;line-height: 94%;text-align: right;">sensitive for pulmonary metastases. There is therefore inadequate evidence that the adoption of routine FDG PET/CT would significantly alter management or prognosis. In line with the above findings, the Royal College of Radiologists (RCR) gave guidance (2016) for indications for FDG PET/CT for soft tissue sarcoma as certain high-grade soft tissue sarcomas, such as pleomorphic undifferentiated sarcomas, rhabdomyosarcomas, leiomyosarcomas, synovial sarcomas, and myxoid liposarcomas with FDG PET/CT in search of metastatic disease not seen on staging CT thorax. The guidance also supports the use of FDG PET/CT in distinguishing MPNSTs from be- nign neuromas in patients with neurofibromatosis type 1. The UK guidelines for soft tissue sarcoma (2016) adds that FDG PET/CT may be particularly useful in situations in which extra-thoracic metastases would change management significantly, for ex-</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">ample prior to an amputation (Figure 18.9).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Whole body bone scintigraphy with 99m-technetium-methyldiphosphonate is not commonly used in the management of soft tissue sarcomas, due to the relative rarity of bone metastases. However, 18F-NaF PET/CT has shown some promise in the detec- tion of skeletal metastases in bone and soft tissue sarcoma which is an area for future investigation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">18.3 <span class="h4">Vascular imaging and interventional radiology</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT and MR angiography (CTA and MRA) are rarely performed but can be useful in determining the vascular anatomy around a lesion for the purpose of embolization and surgical planning. In general, CTA has a better spatial resolution and lower cost com- pared to MRA (Figure 18.10). Given that the majority of soft tissue sarcoma metastases</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="185" alt="image" src="Image_279.png"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">X</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">X</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">X</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 18.9 <span class="s52">a 60-year-old female with spindle cell sarcoma in the posterior right thigh. FDG pet Mip image (a) demonstrates the right thigh primary lesion (X) and metastases (arrowheads). Background uptake also noted in the brain, heart, bowel and renal system. sagittal Ct image of the spine (b), corresponding FDG pet (c) and fused pet/Ct</span></p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">(d) image shows uptake in lesions in the t6/7, l1, l4 vertebral bodies; posterior elements of the t4 vertebral body; and skull base. axial FDG pet/Ct image (e) of the right thigh lesion and three months later (f) shows reduced FDG uptake and only at the periphery of the necrotic mass post radiotherapy.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">are in the lung, and this is an area that lends itself well to radiofrequency ablation. There are a number of series demonstrating the acceptability and good local control rates al- lowed by this technique, but larger scale, randomized studies are needed.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">18.4 <span class="h4">Response to treatment</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Response to treatment may be assessed following primary chemotherapy or radio- therapy or following the definitive surgery as a baseline prior to routine follow-up. This is usually assessed with MRI. Following radiotherapy, the size of the sarcoma may increase due to necrosis and there may be local oedema. The size may conversely decrease following radiotherapy (Figure 18.11). Small-scale studies have suggested that FDG PET/CT may be useful in evaluating response to chemotherapy and radio- therapy, but further studies are needed for clarification.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">18.5 <span class="h4">Follow-up</span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="227" height="388" alt="image" src="Image_280.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A combination of clinical assessment, radiograph, CT, and MRI is used during follow-up to assess for recurrence, which can be in the form of local or distant metastatic disease.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 18.10 <span class="s52">a 61-year-old male with a mesenteric sarcoma supplied by a large hypertrophied ileal branch arising from the main trunk of the superior mesenteric artery. Ct angiography images in the arterial phase in axial (a) and coronal (b) planes demonstrate the enhancing tumour and feeding vessels.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="206" alt="image" src="Image_281.png"/></span></p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 18.11 <span class="s52">t1-weighted axial (a, d), t2-weighted fat saturated axial (b, e) and t1- weighted post contrast fast-saturated axial MRi images (c, f) of a myxofibrosarcoma in the lateral lower leg in a 69-year-old female pre- (a–c) and post- (d–e) radiotherapy. Whereas the sarcoma initially enhances almost homogenously post iV gadolinium, following radiotherapy there is central necrosis with central, non-enhancing fluid, and only residual peripheral enhancing sarcoma.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The choice of imaging depends on the risk of recurrence, the age of the patient (in view of the risks of secondary malignancy from radiation), and the site of the primary.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18.5.1 <span class="s29">Local recurrence</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Recurrence following radical treatment is usually nodular, with signal characteristics of the original sarcoma. MRI post intravenous gadolinium can aid differentiation of recurrence from post-surgical changes such as scarring, infection, or fluid collections (Figure 18.12). FDG PET/CT can also be useful in addition to MRI if the primary was known to have a high SUV, and as a problem-solving tool with MRI to investigate</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="428" height="141" alt="image" src="Image_282.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 18.12 <span class="s52">t1-weighted axial (a), t2-weighted fat saturated axial (b), and t1-weighted post contrast fast-saturated axial (c). MRi images demonstrate post-surgical change in this 60-year-old female following surgical excision of a spindle cell/pleiomorphic sarcoma in the vastus lateralis muscle. there is a postoperative seroma (arrow). anteriorly, a small focus of enhancement post iV gadolinium is concerning for local recurrence (arrowhead).</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">equivocal cases. There should be interval imaging of the primary site (in general this is MRI for primaries of the extremity and CT for primaries of the trunk).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">18.5.2 <span class="s29">Metastatic disease</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A chest radiograph may be sufficient to screen for pulmonary metastases in low-risk disease or elderly patients, but a CT thorax may be preferable for high-risk histology or following a pulmonary metastatectomy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">18.6 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">US, CT, and MRI all play a major role in the investigation of soft tissue sarcomas, with MRI the most influential in terms of diagnosis, treatment planning, and follow-up.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Biopsy is always needed to determine histological subtype and grade.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Further studies will clarify the role of FDG PET/CT in the diagnosis and staging of soft tissue sarcomas.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: justify;">Further reading</p><p class="s74" style="padding-top: 5pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Amini B</b>, <b>Jessop A</b>, <b>Ganeshan D</b>, <b>Tseng W</b>, <b>Madewell J </b>(2014). Contemporary imaging of soft tissue sarcomas. <i>Journal of Surgical Oncology</i>, <b>111</b><a href="https://doi.org/10.1002/jso.23801" class="a" target="_blank">(5): 496–503. https://doi.org/10.1002/ </a><a href="https://doi.org/10.1002/jso.23801" target="_blank">jso.23801</a></p><p class="s75" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Chee D<span class="s74">, </span>Peh W<span class="s74">, </span>Shek T <span class="s74">(2011). Pictorial essay: imaging of peripheral nerve sheath tumours.</span></p><p class="s74" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>Canadian Association Radiologists Journal</i>, <b>62</b>(3): 176–182.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: justify;"><b>Dangoor A</b>, <b>Seddon B</b>, <b>Gerrand C</b>, <b>Grimer R</b>, <b>Whelan J</b>, <b>Judson I </b>(2016). UK guidelines for the management of soft tissue sarcomas. <i>Clinical Sarcoma Research</i>, <b>6</b>(1): 20. doi:10.1186/ s13569-016-0060-4.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: justify;"><b>De Baere T</b>, <b>Tselikas L</b>, <b>Gravel G, et al. </b>(2018). Interventional radiology: role in the treatment of sarcomas. <i>European Journal of Cancer</i>, <b>97</b>: 148–155.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>De La Hoz Polo M</b>, <b>Dick E</b>, <b>Bhumbra R</b>, <b>Pollock R</b>, <b>Sandhu R</b>, <b>Saifuddin A </b>(2017). Surgical considerations when reporting MRI studies of soft tissue sarcoma of the limbs. <i>Skeletal Radiology</i>, <b>46</b>(12): 1667–1678.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Jackson T</b>, <b>Mosci C</b>, <b>von Eyben R, et al. </b>(2015). Combined 18F-NaF and 18F-FDG PET/CT in the evaluation of sarcoma patients. <i>Clinical Nuclear Medicine</i>, <b>40</b>(9): 720–724.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Levy A</b>, <b>Manning M</b>, <b>Al-Refaie W</b>, <b>Miettinen M </b>(2017). Soft-tissue sarcomas of the abdomen and pelvis: radiologic-pathologic features, Part 1—Common sarcomas: from the Radiologic Pathology Archives. <i>RadioGraphics</i>, <b>37</b>(2): 462–483. doi:10.1148/rg.2017160157</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Messiou C</b>, <b>Moskovic E</b>, <b>Vanel D, et al. </b>(2017). Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. <i>European Journal of Surgical Oncology</i>, <b>43</b>(7): 1191–1198.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Roberge D</b>, <b>Vakilian S</b>, <b>Alabed Y</b>, <b>Turcotte R</b>, <b>Freeman C</b>, <b>Hickeson M </b>(2012). FDG PET/CT in initial staging of adult soft-tissue sarcoma. <i>Sarcoma</i>, 2012: 1–7.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Sobin LH</b>, <b>Gospodarowicz MK</b>, <b>Wittekind CH (2017)</b>. <i>UICC TNM Classification of Malignant Tumours </i>(eighth edn). Oxford: Wiley Blackwell.</p><p class="s75" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: left;">van Vliet M<span class="s74">, </span>Kliffen M<span class="s74">, </span>Krestin G<span class="s74">, </span>van Dijke C <span class="s74">(2009). Soft tissue sarcomas at a</span></p><p class="s74" style="padding-left: 24pt;text-indent: 0pt;text-align: left;">glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. <i>European Radiology</i>, <b>19</b><a href="https://doi.org/10.1007/s00330-008-1292-3" class="a" target="_blank">(6): 1499–1511. </a><a href="https://doi.org/10.1007/s00330-008-1292-3" target="_blank">https://doi.org/10.1007/s00330-008-1292-3</a></p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part23.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part25.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
